AR088641A1 - Compuestos de heteroaril piridona y aza-piridona - Google Patents

Compuestos de heteroaril piridona y aza-piridona

Info

Publication number
AR088641A1
AR088641A1 ARP120104128A ARP120104128A AR088641A1 AR 088641 A1 AR088641 A1 AR 088641A1 AR P120104128 A ARP120104128 A AR P120104128A AR P120104128 A ARP120104128 A AR P120104128A AR 088641 A1 AR088641 A1 AR 088641A1
Authority
AR
Argentina
Prior art keywords
heterocyclyl
heteroaryl
alkyl
nhch3
carbocyclyl
Prior art date
Application number
ARP120104128A
Other languages
English (en)
Spanish (es)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR088641A1 publication Critical patent/AR088641A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP120104128A 2011-11-03 2012-11-02 Compuestos de heteroaril piridona y aza-piridona AR088641A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161555393P 2011-11-03 2011-11-03

Publications (1)

Publication Number Publication Date
AR088641A1 true AR088641A1 (es) 2014-06-25

Family

ID=47146779

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP120104128A AR088641A1 (es) 2011-11-03 2012-11-02 Compuestos de heteroaril piridona y aza-piridona
ARP190103844A AR117501A2 (es) 2011-11-03 2019-12-23 Compuestos de heteroaril piridona y aza-piridona

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP190103844A AR117501A2 (es) 2011-11-03 2019-12-23 Compuestos de heteroaril piridona y aza-piridona

Country Status (34)

Country Link
US (11) US8716274B2 (en:Method)
EP (5) EP2773638B1 (en:Method)
JP (5) JP5976827B2 (en:Method)
KR (2) KR101659193B1 (en:Method)
CN (2) CN107011348B (en:Method)
AR (2) AR088641A1 (en:Method)
AU (5) AU2012332365B2 (en:Method)
CA (1) CA2853975C (en:Method)
CL (1) CL2014001103A1 (en:Method)
CO (1) CO6950472A2 (en:Method)
CR (1) CR20140194A (en:Method)
CY (1) CY1117097T1 (en:Method)
DK (2) DK3002284T3 (en:Method)
EA (1) EA023263B1 (en:Method)
ES (3) ES2898938T3 (en:Method)
HR (2) HRP20151442T1 (en:Method)
HU (2) HUE044959T2 (en:Method)
IL (1) IL232060A (en:Method)
IN (1) IN2014CN03250A (en:Method)
LT (1) LT3002284T (en:Method)
MA (1) MA35819B1 (en:Method)
MX (2) MX2014005331A (en:Method)
PE (1) PE20141586A1 (en:Method)
PH (1) PH12014500936A1 (en:Method)
PL (3) PL2773638T3 (en:Method)
PT (2) PT2773638E (en:Method)
RS (2) RS59016B1 (en:Method)
SG (1) SG11201401992YA (en:Method)
SI (2) SI2773638T1 (en:Method)
TR (1) TR201909849T4 (en:Method)
TW (4) TW202124384A (en:Method)
UA (1) UA111756C2 (en:Method)
WO (1) WO2013067274A1 (en:Method)
ZA (1) ZA201804727B (en:Method)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014CN03265A (en:Method) * 2011-11-03 2015-07-03 Hoffmann La Roche
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
WO2015000949A1 (en) 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone amide compounds
WO2015050703A1 (en) * 2013-10-04 2015-04-09 Yi Chen Inhibitors of bruton's tyrosine kinase
CA2929918C (en) * 2013-12-05 2018-01-23 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
EP3201186B1 (en) 2014-10-02 2019-02-27 F. Hoffmann-La Roche AG Pyrazole carboxamide compounds for use in the treament of disorders mediated by bruton's tyrosine kinase (btk)
EP3212645B1 (en) * 2014-10-27 2018-11-28 F.Hoffmann-La Roche Ag Process for making tricyclic lactam compounds
CN106188063A (zh) * 2015-05-08 2016-12-07 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途
UY36875A (es) 2015-09-02 2017-03-31 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
US10208024B2 (en) 2015-10-23 2019-02-19 Array Biopharma Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
BR112018016842A2 (pt) * 2016-02-19 2018-12-26 Novartis Ag compostos de piridona tetracíclica como antivirais
ES2913494T3 (es) * 2016-02-29 2022-06-02 Hoffmann La Roche Composiciones de forma farmacéutica que comprenden un inhibidor de tirosina cinasa de Bruton
WO2017186668A1 (en) * 2016-04-28 2017-11-02 F. Hoffmann-La Roche Ag A process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
MX2019006288A (es) 2016-12-03 2020-10-01 Juno Therapeutics Inc Metodos y composiciones para el uso de celulas t terapeuticas en combinacion con inhibidores de quinasa.
CA3046961A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
WO2018109050A1 (en) * 2016-12-15 2018-06-21 F. Hoffmann-La Roche Ag Process for preparing btk inhibitors
DK3559000T3 (da) 2016-12-22 2022-06-07 Betta Pharmaceuticals Co Ltd Benzimidazol-derivater, fremgangsmåder til fremstilling og anvendelser deraf
JP2020514384A (ja) * 2017-03-24 2020-05-21 ジェネンテック， インコーポレイテッド 自己免疫及び炎症性疾患を治療する方法
CN107445981B (zh) * 2017-08-25 2018-06-22 牡丹江医学院 一种用于防治宫颈炎的活性化合物
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
WO2019082143A1 (en) 2017-10-27 2019-05-02 Fresenius Kabi Oncology Ltd. IMPROVED PROCESS FOR THE PREPARATION OF RIBOCICLIB AND ITS SALTS
US11100492B2 (en) * 2018-02-19 2021-08-24 Peter Garrett General purpose re-loadable card aggregation implementation
WO2019177937A1 (en) 2018-03-12 2019-09-19 Arbutus Biopharma, Inc. Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
WO2019208805A1 (ja) 2018-04-27 2019-10-31 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
ES2988933T3 (es) 2018-06-07 2024-11-22 Disarm Therapeutics Inc Inhibidores de SARM1
WO2020021447A1 (en) 2018-07-25 2020-01-30 Novartis Ag Nlrp3 inflammasome inhibitors
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
CA3111126A1 (en) 2018-08-31 2020-03-05 Stichting Katholieke Universiteit Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof
EP3867242A1 (en) 2018-10-15 2021-08-25 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
JP2022515197A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
TW202033523A (zh) * 2019-01-17 2020-09-16 美商愛彼特生物製藥股份有限公司 經取代的多環羧酸、其類似物及使用其之方法
KR20210119457A (ko) 2019-01-22 2021-10-05 에프. 호프만-라 로슈 아게 브루톤 티로신 키나제 억제제를 이용한 류마티스 관절염, 만성 자발성 두드러기 및 전신 홍반 루푸스의 치료 방법
US20220135569A1 (en) 2019-02-25 2022-05-05 Newave Pharmaceutical Inc. Inhibitor of btk and mutants thereof
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
EP3953346A1 (en) 2019-04-09 2022-02-16 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
US11530229B2 (en) 2019-05-17 2022-12-20 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
CA3144450A1 (en) 2019-06-26 2020-12-30 Nurix Therapeutics, Inc. Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof
WO2021066958A1 (en) 2019-10-05 2021-04-08 Newave Pharmaceutical Inc. Inhibitor of btk and mutants thereof
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
EP4055019B1 (en) * 2019-11-08 2025-01-22 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
DK4069237T3 (da) 2019-12-04 2025-06-23 Nurix Therapeutics Inc Bifunktionelle forbindelser til nedbrydning af btk via ubiquitinproteosomvejen
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN119930630A (zh) 2020-02-20 2025-05-06 和记黄埔医药（上海）有限公司 杂芳基杂环化合物及其用途
EP4110339A1 (en) 2020-02-28 2023-01-04 Genentech, Inc. Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase
WO2021202825A1 (en) 2020-04-03 2021-10-07 Genentech, Inc. Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase
CN115715291B (zh) * 2020-06-18 2025-04-29 上海华汇拓医药科技有限公司 布鲁顿酪氨酸激酶抑制剂及其制备方法
US20230295109A1 (en) * 2020-08-04 2023-09-21 Hoffmann-La Roche Inc. Pyridinone compounds for the treatment of autoimmune disease
EP4196124A1 (en) * 2020-08-14 2023-06-21 Guangzhou Lupeng Pharmaceutical Company Ltd. Dosage form compositions comprising an inhibitor of btk and mutants thereof
KR20230051227A (ko) 2020-08-14 2023-04-17 노파르티스 아게 헤테로아릴 치환된 스피로피페리디닐 유도체 및 이의 제약 용도
CN116568687B (zh) 2020-09-21 2025-09-02 和记黄埔医药（上海）有限公司 杂芳基杂环化合物及其用途
US20230382900A1 (en) 2020-10-30 2023-11-30 Newave Pharmaceutical Inc. Inhibitors of btk
WO2022133184A1 (en) 2020-12-20 2022-06-23 Newave Pharmaceutical Inc. Btk degrader
US20240216330A1 (en) 2021-04-02 2024-07-04 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
MX2023011883A (es) 2021-04-08 2023-11-09 Nurix Therapeutics Inc Terapias combinadas con compuestos inhibidores de cbl-b.
HUE070539T2 (hu) 2021-05-05 2025-06-28 Hoffmann La Roche Eljárás BTK-inhibitorok elõállítására
CN113603685A (zh) * 2021-07-23 2021-11-05 都创(上海)医药开发有限公司 Fenebrutinib化合物的晶型及其制备方法和用途
WO2023076303A1 (en) 2021-10-26 2023-05-04 Nurix Therapeutics, Inc. Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
CA3241069A1 (en) 2021-12-14 2023-06-22 Adrianus Petrus Antonius De Man Macrocyclic btk inhibitors
WO2023137225A1 (en) * 2022-01-17 2023-07-20 Newave Pharmaceutical Inc. Btk degrader
TW202346276A (zh) 2022-01-27 2023-12-01 日商田邊三菱製藥股份有限公司 新穎之ｂ０ａｔ１抑制劑
EP4471012A1 (en) 2022-01-28 2024-12-04 HUTCHMED Limited Synthesis method for 7,8-dihydro-2h-cyclopentapyrrolopyrazinone compound
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
TW202508592A (zh) 2023-05-16 2025-03-01 美商建南德克公司 使用布魯頓酪胺酸激酶之抑制劑來治療復發型多發性硬化症之方法
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
WO2025031344A1 (zh) * 2023-08-07 2025-02-13 广州麓鹏制药有限公司 一种丙烯酰胺类化合物的晶型vi及其制备方法和用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
WO2003006151A1 (en) 2001-07-12 2003-01-23 Avecia Limited Microencapsulated catalyst, methods of preparation and methods of use thereof
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
EP1773348A4 (en) 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc TETRA PEPTIDE ANALOGS
BRPI0517619A (pt) 2004-11-10 2008-10-14 Cgi Pharmaceuticals Inc entidades quìmicas de imidazo[1,2-a] pirazin-8-ilaminas, suas composições farmacêuticas, uso dos referidos compostos na preparação de medicamento, processo de preparação de medicamento e métodos de utilização dos referidos compostos
CN101223141A (zh) 2005-03-10 2008-07-16 Cgi药品股份有限公司 特定取代的酰胺，其制备方法和使用方法
EP1934174B1 (en) 2005-10-07 2011-04-06 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
AR063706A1 (es) 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
PT2529622T (pt) * 2006-09-22 2018-04-24 Pharmacyclics Llc Inibidores de tirosina cinase de bruton
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CN101835755B (zh) * 2007-10-23 2013-12-11 霍夫曼-拉罗奇有限公司 激酶抑制剂
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
JP5259739B2 (ja) * 2008-02-05 2013-08-07 エフ．ホフマン−ラ ロシュ アーゲー 新規ピリジノン及びピリダジノン
US7683064B2 (en) 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2297105B1 (en) 2008-05-06 2015-09-02 Gilead Connecticut, Inc. Substituted amides, method of making, and use as btk inhibitors
PH12012502374A1 (en) 2008-06-24 2014-11-12 Hoffmann La Roche Novel substituted pyridin-2-ones and pyridazin-3-ones
DK2300459T3 (da) 2008-07-02 2013-09-02 Hoffmann La Roche Nye fenylpyrazinoner som kinasehæmmere
CA2636807A1 (en) 2008-07-04 2010-01-04 Steven Splinter Methods for obtaining cyclopamine
ES2552681T3 (es) 2008-07-15 2015-12-01 F. Hoffmann-La Roche Ag Nuevas fenil-imidazopiridinas y piridazinas
WO2010056875A1 (en) 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
ES2513915T3 (es) * 2009-04-24 2014-10-27 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
WO2010126960A1 (en) * 2009-04-29 2010-11-04 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
CN102711473B (zh) * 2009-09-04 2016-11-09 比奥根Ma公司 布鲁顿酪氨酸激酶抑制剂
NZ604004A (en) * 2010-05-07 2014-06-27 Gilead Connecticut Inc Pyridone and aza-pyridone compounds and methods of use
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
ES2561277T3 (es) 2010-09-01 2016-02-25 Gilead Connecticut, Inc. Piridinonas/pirazinonas, procedimiento de preparación y procedimiento de utilización de las mismas
BR112013007499A2 (pt) 2010-09-01 2016-07-12 Genentech Inc piridazinonas - métodos de criação e usos
JP5859640B2 (ja) 2011-05-17 2016-02-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼ阻害剤
CA2841801A1 (en) 2011-08-17 2013-02-21 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
IN2014CN03265A (en:Method) * 2011-11-03 2015-07-03 Hoffmann La Roche
CA2853967A1 (en) * 2011-11-03 2013-05-10 F. Hoffmann-La Roche Ag 8-fluorophthalazin-1 (2h) -one compounds as inhibitors of btk activity
WO2015000949A1 (en) * 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone amide compounds
CA2929918C (en) * 2013-12-05 2018-01-23 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
ES2913494T3 (es) * 2016-02-29 2022-06-02 Hoffmann La Roche Composiciones de forma farmacéutica que comprenden un inhibidor de tirosina cinasa de Bruton

Also Published As

Publication number Publication date
BR112014010459A2 (pt) 2017-04-18
US20140378432A1 (en) 2014-12-25
HRP20191307T1 (hr) 2019-10-18
JP2016028046A (ja) 2016-02-25
AU2018201557B2 (en) 2019-09-19
PE20141586A1 (es) 2014-10-25
TW202124384A (zh) 2021-07-01
EP2773638B1 (en) 2015-10-07
EP3002284B1 (en) 2019-05-22
RS54505B1 (sr) 2016-06-30
JP2019108342A (ja) 2019-07-04
JP6571215B2 (ja) 2019-09-04
PL3521288T3 (pl) 2021-12-27
IN2014CN03250A (en:Method) 2015-07-03
AU2020202707B2 (en) 2021-09-02
USRE48239E1 (en) 2020-10-06
AU2012332365B2 (en) 2016-09-15
US8921353B2 (en) 2014-12-30
EP4050012A1 (en) 2022-08-31
AU2019216728A1 (en) 2019-09-05
DK2773638T3 (en) 2015-10-19
AU2019216728B2 (en) 2020-04-09
IL232060A0 (en) 2014-05-28
HUE044959T2 (hu) 2019-12-30
LT3002284T (lt) 2019-08-12
US20190194203A1 (en) 2019-06-27
HUE028019T2 (en) 2016-11-28
SG11201401992YA (en) 2014-05-29
UA111756C2 (uk) 2016-06-10
JP2020183397A (ja) 2020-11-12
TWI652270B (zh) 2019-03-01
AU2012332365A1 (en) 2014-05-01
CN104125959A (zh) 2014-10-29
MA35819B1 (fr) 2014-12-01
ZA201804727B (en) 2023-03-29
TR201909849T4 (tr) 2019-07-22
US20160228432A1 (en) 2016-08-11
EA023263B1 (ru) 2016-05-31
AR117501A2 (es) 2021-08-11
US20210079002A1 (en) 2021-03-18
TW201326175A (zh) 2013-07-01
US20130116235A1 (en) 2013-05-09
CN104125959B (zh) 2017-05-03
RS59016B1 (sr) 2019-08-30
JP5976827B2 (ja) 2016-08-24
EA201490858A1 (ru) 2014-08-29
JP2018080193A (ja) 2018-05-24
PH12014500936A1 (en) 2014-06-09
WO2013067274A1 (en) 2013-05-10
CN107011348B (zh) 2020-01-10
US20140194408A1 (en) 2014-07-10
PL2773638T3 (pl) 2016-03-31
SI3002284T1 (sl) 2019-08-30
TWI609868B (zh) 2018-01-01
US20180071286A1 (en) 2018-03-15
SI2773638T1 (sl) 2015-12-31
EP3002284A1 (en) 2016-04-06
DK3002284T3 (da) 2019-07-29
IL232060A (en) 2016-02-29
TWI701250B (zh) 2020-08-11
TW201906845A (zh) 2019-02-16
EP2773638A1 (en) 2014-09-10
EP4019508A1 (en) 2022-06-29
KR20140096097A (ko) 2014-08-04
US20240270747A1 (en) 2024-08-15
MX361807B (es) 2018-12-17
AU2020202707A1 (en) 2020-05-14
ES2555168T3 (es) 2015-12-29
AU2018201557A1 (en) 2018-03-22
NZ624021A (en) 2016-09-30
CA2853975A1 (en) 2013-05-10
US10045983B2 (en) 2018-08-14
US8716274B2 (en) 2014-05-06
TW201741315A (zh) 2017-12-01
CO6950472A2 (es) 2014-05-20
PL3002284T3 (pl) 2019-11-29
US20200062769A1 (en) 2020-02-27
US20230279012A1 (en) 2023-09-07
CR20140194A (es) 2014-06-03
JP2014532762A (ja) 2014-12-08
CY1117097T1 (el) 2017-04-05
KR101659193B1 (ko) 2016-09-22
CA2853975C (en) 2020-02-25
ES2898938T3 (es) 2022-03-09
HK1201265A1 (en) 2015-08-28
US9238655B2 (en) 2016-01-19
AU2016273930A1 (en) 2017-01-12
PT2773638E (pt) 2016-01-12
AU2016273930B2 (en) 2018-03-08
US9782405B2 (en) 2017-10-10
KR20160003328A (ko) 2016-01-08
MX2014005331A (es) 2014-05-28
CN107011348A (zh) 2017-08-04
PT3002284T (pt) 2019-07-17
CL2014001103A1 (es) 2014-10-03
HRP20151442T1 (hr) 2016-01-29
ES2738329T3 (es) 2020-01-22
EP3521288A1 (en) 2019-08-07
EP3521288B1 (en) 2021-09-08

Similar Documents

Publication Publication Date Title
AR117501A2 (es) Compuestos de heteroaril piridona y aza-piridona
AR088643A1 (es) Compuestos de 8-fluoroftalazin-1(2h)-ona
AR088061A1 (es) Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
AR085683A1 (es) Compuestos de piridona y aza-piridona y metodos de uso
AR088642A1 (es) Compuestos de piperazina alquilados
AR122019A2 (es) Compuestos tricíclicos inhibidores de la pi3k y métodos de uso
AR111281A1 (es) Compuestos de pirimidinil-piridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
MX2014014828A (es) Compuestos de 5-azaindazol y metodos de uso.
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
AR095308A1 (es) Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento
EA201590624A1 (ru) Циклические эфиры пиразол-4-ил-гетероциклил-карбоксамидных соединений и способы их применения
MX2014005285A (es) Compuestos biciclicos de piperazina.
CY1119714T1 (el) Ενωσεις αναστολεων
MX2015018038A (es) Compuestos de heteroaril-piridona y aza-piridona-amida.
AR085004A1 (es) Inhibidores selectivos de glicosidasas y usos de los mismos
AR067346A1 (es) Derivados de bencimidazol
AR088748A1 (es) Macrociclos como inhibidores del factor xia
UA116774C2 (uk) Інгібітори серин/треонінкінази
AR087127A1 (es) Compuestos que se unen a fxr (nr1h4) y modulan su actividad
EA027213B9 (ru) Соединения пиразолопиримидина в качестве ингибиторов киназ
MX392440B (es) Inhibidores de tirosina quinasa de bazo (syk).
AR067886A1 (es) Derivados de acido azabifenilaminobenzoico
CO6620072A2 (es) Compuestod de benzoxepina inhibidores de la pi3k y métodos de uso

Legal Events

Date Code Title Description
FG Grant, registration